echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chinese officials have confirmed that the domestic new crown vaccine has been granted a patent

    Chinese officials have confirmed that the domestic new crown vaccine has been granted a patent

    • Last Update: 2020-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, Aug. 18 (Reporter Sun Zifa) in response to the recent online information on the approval of domestic new crown vaccine patents, China's State Intellectual Property Office announced on the 18th, confirmed that the
    jun" military medical research institute Chen Wei
    team and Consino Bio jointly declared the new crown vaccine patent application has been granted patent rights" situation is true. Patent applications for the invention enjoy a priority examination policy.
    According to the State Intellectual Property Office, after nuclear, the vaccine patent application invention name is "a human reproduction defect adenovirus as the carrier of the recombination of a new type of coronavirus vaccine", the patent application number is 202010193587.8, the applicant is Chinese MIN Military
    Military Medicine" Research Institute and Concino Biological Co., Ltd., inventor Chen Wei, etc., the application date is March 18, 2020, after submitting a priority examination request, the State Intellectual Property Office issued a patent authorization notice on August 11, 2020, pending the applicant in accordance with the law to go through the patent registration procedures, the Office will announce the authorization of the patent.
    State Intellectual Property Office noted that patent applications for new crown vaccine inventions enjoyed a priority review policy. Since the outbreak of neo-crown pneumonia, the State Intellectual Property Office attaches great importance to the patent examination business to the outbreak prevention and control and response support. On February 15, 2020, the State Administration of Market Supervision, the State Drug Administration and the State Intellectual Property Office jointly issued Article 10 of Support for the Resumption of Work and Production, Article 3 of which stipulates that patent applications and trademark registrations involving the prevention and treatment of new crown pneumonia shall be examined and processed as a matter of priority upon request.
    At the same time, the State Intellectual Property Office has conducted priority examination on request for various patent applications or cases involving the prevention and treatment of neo-crown pneumonia, such as new crown pneumonia treatment and preventive drugs and vaccines, testing methods and instruments, masks, goggles, disinfectants and other protective products and methods. The contents of the patent application relate to the prevention and treatment technology of the outbreak of new crown pneumonia, which belongs to the situation that can be examined as a priority as stipulated in the Measures for the Administration of Priority Examination of Patents, and also conforms to the relevant provisions of article 10 of the "Ten Articles on The Resumption of Work and Production". After the applicant has made a request for priority examination, the State Intellectual Property Office considers that it meets the priority examination criteria and follows the priority examination procedure.
    State Intellectual Property Office said it strictly enforces its policy on all patent applications related to the prevention and treatment of the outbreak of neo-crown pneumonia and gives priority to review and support in a fair and impartial basis.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.